Pfizer (PFE)
$28.05
0.00 (0.00%)
PFE Stock Quote Delayed 30 Minutes
Pfizer Inc. May Get FDA Ok to Remove ‘Black Box’ Warning From Chantix
Pfizer (PFE) may gain approval to remove its 'Black Box' warning from its smoking addiction medicine Chantix, which may have adverse side-effects.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
157.27B
PE Ratio
-561.00
EPS
-0.05
Volume (Avg. Vol.)
33,740
Day's Range
-
52-Week Range
$25.20 - $37.80
Dividend & Yield
$1.64 (5.85%)
PFE Stock Predictions, Articles, and Pfizer News
There’s More to Johnson & Johnson (JNJ) Than Meets the Eye
Johnson & Johnson (JNJ) has an impressive pipeline most investors don't fully appreciate. This isn't your father's stock.
Merck & Co., Inc. Features Slow and Steady Dividend Growth (MRK)
Merck is a blue-chip dividend stock that may be a solid investment, however MRK's dividend growth lags other competitors
PFE, AZN: Pfizer Inc. to Buy AstraZeneca plc (ADR)’s Antibiotic Business
Pfizer (PFE) has announced that it will be acquiring part of AstraZeneca's (AZN) antibiotic business outside the US for $725 million.
Stocks Finish Mixed Amid Summer Doldrums
In the end, the Dow Jones lost 0.1%, the S&P 500 lost 0.1%, the Nasdaq gained 0.1% and the Russell 2000 gained 0.2%.
Pfizer Inc. (PFE) Adds Oncology Muscle With Medivation Inc (MDVN)
Whether Pfizer (PFE) splits up or not, its growing footprint in blockbuster cancer drugs promises more outperformance to come.
Why Cray Inc. (CRAY), Kate Spade & Co (KATE) and Pfizer Inc. (PFE) Are 3 of Today’s Worst Stocks
Pfizer (PFE), Cray (CRAY) and Kate Spade & Co (KATE) were just obliterated by disappointing quarterly numbers and outlooks today.
Pfizer Inc.: Why PFE Stock Still Bleeds Despite Solid Earnings
Pfizer's (PFE) better-than-expected earnings were overshadowed by a disappointing forecast and lack of news on a potential split.
Trade of the Day: PFE Stock Still in a Healthy Bull Market
A breakout from a triple-top led to a new all-time high in Pfizer Inc.
Pfizer Inc. (PFE) Stock: 3 Pros, 3 Cons
Pfizer (PFE) is a low volatility, dependable dividend payer. That can add ballast to your portfolio -- but it could also weigh it down.
Carl Icahn Takes Stake in Allergan plc Ordinary Shares (AGN) Stock
Allergan stock was up on Tuesday after news that Carl Icahn had taken a 'large' stake in the company, but details weren't revealed.
4 Pharmaceuticals Stocks to Buy Now
The grades of 4 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Wednesday’s Vital Data: Amazon.com, Inc. (AMZN), Pfizer Inc. (PFE) and Walt Disney Co (DIS)
Walt Disney (DIS) options to fall flat on earnings, Pfizer (PFE) calls surge on ex-dividend and Amazon.com (AMZN) speculation explodes after the stock gets a $1,000 price target.
These 68 Blue Chips Are on the Move
During these times it pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start with these blue chip stock moves
Why Fidelity National Information Services (FIS), Pfizer Inc. (PFE) and Yelp Inc (YELP) Are 3 of Today’s Best Stocks
Although stocks suffered Tuesday, FIS, PFE and YELP had tailwinds on their way to joining the best-stocks-of-the-day club.
Is Pfizer Inc. Finally Safe To Buy Again? (PFE)
A first-quarter earnings and revenue beat has investors excited once again with formerly beat-down Pfizer Inc. Is now the time to buy PFE?
